SCHWARZ PHARMA secures future neurology projects
SCHWARZ PHARMA acquires the worldwide rights to all substances originating from this cooperation that prove effective in the treatment of neuro-degenerative diseases. The project is at the early pre-clinical stage.
"This cooperation adds further attractive potential to our development pipeline. With Professor Feuerstein from the Neurologischen Univer-sitätsklinik, we have gained an excellent partner with a high international reputation in the field of neuropharmacology." said Dr. Dr. Lars Ekman, Executive Board member of SCHWARZ PHARMA AG and responsible for Research and Development. "Our aim is to continue expanding our CNS pipeline. For this reason, we are constantly exam-ining promising opportunities. We are confident that further innovative projects will follow this year."
Most read news
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.